Clinical Trials Logo

Cholangitis, Sclerosing clinical trials

View clinical trials related to Cholangitis, Sclerosing.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05396755 Terminated - Clinical trials for Secondary Sclerosing Cholangitis

Biliary Interventions in Critically Ill Patients With Secondary Sclerosing Cholangitis (BISCIT)

BISCIT
Start date: November 14, 2022
Phase: N/A
Study type: Interventional

This is a randomized, open-label, controlled, parallel group, multicenter clinical trial. Patients with confirmed secondary sclerosing cholangitis (SSC-CIP) will be randomized either in the intervention group undergoing scheduled invasive evaluation of the biliary tract or in the control group treated with non-interventional standard of care to demonstrate that programmed endoscopic therapy compared to a conservative strategy reduces the occurrence of treatment failures.

NCT ID: NCT04060147 Terminated - Clinical trials for Primary Sclerosing Cholangitis

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

Start date: October 17, 2019
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to assess the safety and tolerability of escalating doses of cilofexor (CILO) in participants with primary sclerosing cholangitis (PSC) and compensated cirrhosis.

NCT ID: NCT03890120 Terminated - Clinical trials for Primary Sclerosing Cholangitis

Study of Cilofexor in Adults With Primary Sclerosing Cholangitis

PRIMIS
Start date: March 27, 2019
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate whether cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).

NCT ID: NCT03394781 Terminated - Clinical trials for Primary Sclerosing Cholangitis

A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)

Start date: January 22, 2018
Phase: Phase 2
Study type: Interventional

This is a research trial testing DUR-928 (an experimental medication). The purpose of the trial is to assess whether treatment with DUR-928 has any effect on the treatment of Primary Sclerosing Cholangitis (PSC). This trial will also assess safety (side effects).

NCT ID: NCT03359174 Terminated - Clinical trials for Cholangitis, Sclerosing

An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis

Start date: May 29, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine whether a low dose of ATRA will improve laboratory tests of liver and bile duct inflammation in patients with PSC. The investigators will also look for changes to other blood tests which are related to inflammation, scarring, and the immune system.

NCT ID: NCT01142323 Terminated - Clinical trials for Primary Sclerosing Cholangitis

Pilot Study of Fenofibrate for PSC

Start date: October 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether fenofibrate is safe and effective in the treatment primary sclerosing cholangitis (PSC).

NCT ID: NCT00953615 Terminated - Clinical trials for Primary Sclerosing Cholangitis

Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)

Start date: April 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and benefit of Thalidomide with primary sclerosing cholangitis (PSC). This is a six month study.

NCT ID: NCT00059202 Terminated - Clinical trials for Primary Sclerosing Cholangitis

Trial of High-dose Urso in Primary Sclerosing Cholangitis

Start date: July 2002
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multicenter, randomized, controlled trial of high dose ursodiol versus placebo for patients with primary sclerosing cholangitis (PSC). The average duration of follow-up will be approximately five years with important clinical endpoints such as death, eligibility for liver transplantation, changes in histology and cholangiogram as well as liver biochemistries and quality of life data collected.